A convenient technology to quantify three-dimensional (3D) morphological features would have widespread applications in biomedical research. Now, researchers from Umea University in Sweden presented a new method for 3D imaging and quantification of biological preparations ten times larger than the limit for traditional confocal microscopes.
GE was the first to undertake molecular imaging development on a large scale. 'You have to be a very special company to work in this discipline,' Reinaldo Garcia, President and Chief Executive Officer of GE Healthcare International, pointed out, when we asked for an update on his company's progress in this field
The European Congress of Radiology (ECR) is a never-ending story of surprises, excitement, and success. Year after year, more scientists, radiologists eager to learn, and partners from industrial companies flock to this excellent meeting.
Aiming for European biomedical research at the highest level.
As information and communications technology (ICT) makes it way into the everyday practice of medicine, the Radiological Society of North America (RSNA) is integrating ICT with clinical presentations at the world's largest healthcare meeting this year.
The First European Institute of Molecular Imaging (EIMI) was foundet at the Westphalian Wilhelms-University in Muenster, Germany.
In an interview with Daniela Zimmermann, Executive Director of European Hospital, Dr Mohammad Naraghi, Head of the Department of Business Development at Siemens Medical Solutions, discussed developments in moleculary medicine, biochips, preventive diagnostics and a comprehensive and integrated health system for the future.
By Stefan G Ruehm MD PhD, Associate Professor of Radiology, at the David Geffen School of Medicine, UCLA, California
Dr Hanns-Joachim Weinmann, Diagnostics and Radiopharmaceuticals, Magnetic Resonance Imaging & X-Ray Research, Schering AG, examines what is feasible and what still lies only at a tantalising distance.
12 distinguished researchers and industry representatives presented the latest molecular medicine research at the Molecular Medicine - from Diagnostics to Therapy symposium - one in a series of annual diagnostics seminars organised by the Forum Medicine Technology & Pharmaceutics e.V.
Generating targeting agents for diagnostics, prognostics and radiotherapy, by designing biochemically specific elements in contrast agents to be the targeting molecules attached to and carrying diagnostic or radiotherapeutic molecules to abnormal cells.
By Dr Fabian Kiessling, Head of the Division of Molecular Imaging, Department of Biophysics and Medical Radiation Physics, German Cancer Research Centre (DKFZ)
Tobias Schaeffter PhD, Principal Scientist, Philips Research Laboratories, Hamburg, Arne Hengerer PhD, Director molecular MR, Siemens Medical Solutions, Erlangen, and Andreas Briel PhD, Eisenherz project manager, Schering Research Laboratories, Berlin, describe...
During the annual meeting of the Society of Nuclear Medicine, in California this June, GE Healthcare announced the first installations of its new Discovery VCT - described as “the world's first true 64-slice combination positron emission tomography and volume computed tomography (PET/CT) system.”
Siemens has signed an agreement with Bayer to acquire the chemical and pharmaceutical company's Diagnostics Division.
Prevention is better than cure - use the technology! A report from the 1st International High Tech in Medicine congress.
Late in November and into early December, as icy air streamed over the shores of Lake Michigan - affirming the nickname `windy city´ for Chicago - radiologists continued to immigrate here en masse for their biggest annual gathering. This year the Radiological Society of North America (RSNA) held its 91st annual meeting, parallel with the scientific congress and trade fair. The exhibition alone…
The decoding of the genome has made it possible for molecular biology specialists to detect predispositions for illnesses and treat them accordingly.
Researchers open up new opportunities for cellular and molecular MR imaging.
Peter Loescher has worked at the cutting edge of the pharmaceutical industry for 17 years. In the latter part of this period, for example, he headed Hoechst's division in Japan, where he was also spokesperson for the European pharmaceutical industry, negotiating with the Japanese government during its healthcare reform in 2002.